



Issuer Hansa Biopharma AB

Holder

Redmile Biopharma Investments III, LP

Instrument

Instrument Stamaktier SE0002148817

Before the transaction

Shares 8,572,934
Voting rights 8,572,934

Transaction

Reason for major shareholding notification Corporate action
Date 11/04/2024
Limit for number of shares 15 %
Limit for number of votes 15 %

After the transaction

Quantity

Shares 9,445,764
Directly held voting rights 9,445,764
Indirectly held voting rights 0

Percentage

Directly held shares 14.41904 %
Directly held voting rights 14.90273 %
Indirectly held voting rights 0 %

Resulting distribution of total holdings

	Percentage of voting rights:	Number of underlying shares:
Shares	14.90273 %	9,445,764

Instruments - FITA Ch. 4, section 2, first paragraph, line 2

Instruments - FITA Ch. 4, section 2, first paragraph, line 3

- Physically settled
- Cash settled

Total	14.90273 %	9,445,764
-------	------------	-----------

Group total holdings

Voting rights 9,445,764
Percentage of voting rights 14.90273

Notes (other relevant informations according to law)

Redmile Biopharma Investments III, LP (the "Shareholder"), a fund managed by Redmile Group, LLC, has participated in the directed share issue in Hansa Biopharma AB (the "Issuer") announced by the Issuer on 12 April 2024 by way of press release. The Shareholder acquired 872,830 new ordinary shares in the directed share issue and the Shareholder's total number of shares after the directed share issue is 9,445,764 ordinary shares. Due to the directed share issue and based on the Issuer's new number of total shares after the First Tranche of the directed share issue, the Shareholder's percentage of total votes has changed from 16.20346% to 14.90273% and the Shareholder's percentage of total shares has changed from 15.57745% to 14.41904%. This notification is filed since the Shareholder's percentage of total votes and total shares in the Issuer went below the 15% threshold following the directed share issue.

Published

16/04/2024 11:23

Contact

Name Stefan Berglöf
Phone 0709725490 Email stefan.berglof@walthon.se

CLOSE

PRINT